PRESS: Global Genes - Forge Biologics

PRESS: Global Genes

Forge Biologics, a viral vector gene therapy manufacturing and development company with a platform to develop proprietary gene therapy products, has launched with $40 million in series A financing.

Perceptive Xontogeny Venture Fund led the funding with participation from Drive Capital. Forge will use the proceeds to expand AAV and for the development of a novel gene therapy pipeline.

Read In Full:

0/5 (0 Reviews)